Avadel Pharmaceuticals PLC expected to post earnings of 3 cents a share - Earnings Preview

Avadel Pharmaceuticals

05/08/2025 15:10

Avadel Pharmaceuticals PLC AVDL.OQ AVDL.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The Dublin-based  company is expected to report a 48.2% increase in revenue to $61.498 million from $41.5 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.The company's guidance on May 7 2025, for the period ended June 30, was for revenue between $60.00 million and $63.00 million.

​LSEG's mean analyst estimate for Avadel Pharmaceuticals PLC is for earnings of 3 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is $16.50, about 31.8% above its last closing price of $11.26

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.08
-0.07
-0.05
Beat
29.8
Dec. 31 2025
-0.04
-0.04
-0.05
Missed
-22.5
Sep. 30 2024
-0.06
-0.06
-0.03
Beat
45.7​
Jun. 30 2024
-0.17
-0.16
-0.14
Beat
10
​​Mar. 31 2024
-0.20
-0.21
-0.30
Missed
-44.4
Dec. 31 2023
-0.23
-0.26
-0.29
Missed
-11.8​
Sep. 30 2023
-0.38
-0.37
-0.41
Missed
-10.1
Jun. 30 2023
-0.38
-0.38
-0.83
Missed
-116

This summary was machine generated August 5 at 14:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)